Alumis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alumis and other ETFs, options, and stocks.About ALMS
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies.
CEOMartin Babler
CEOMartin Babler
Employees168
Employees168
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2021
Founded2021
Employees168
Employees168
ALMS Key Statistics
Market cap1.18B
Market cap1.18B
Price-Earnings ratio-2.98
Price-Earnings ratio-2.98
Dividend yield—
Dividend yield—
Average volume1.51M
Average volume1.51M
High today$11.60
High today$11.60
Low today$11.06
Low today$11.06
Open price$11.56
Open price$11.56
Volume1.07M
Volume1.07M
52 Week high$12.44
52 Week high$12.44
52 Week low$2.76
52 Week low$2.76
Stock Snapshot
With a market cap of 1.18B, Alumis(ALMS) trades at $11.16. The stock has a price-to-earnings ratio of -2.98.
During the trading session on 2025-12-15, Alumis(ALMS) shares reached a daily high of $11.60 and a low of $11.06. At a current price of $11.16, the stock is +0.9% higher than the low and still -3.8% under the high.
Trading volume for Alumis(ALMS) stock has reached 1.07M, versus its average volume of 1.51M.
Over the past 52 weeks, Alumis(ALMS) stock has traded between a high of $12.44 and a low of $2.76.
Over the past 52 weeks, Alumis(ALMS) stock has traded between a high of $12.44 and a low of $2.76.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own ALMS. This list is generated using Robinhood data, and it’s not a recommendation.